Medications are the gold standard for treatment to help curb cravings and block opioid receptors. Drugs developed using the company’s AQL technology have release rates measured in months, not days, enabling (for example) the provision of an entire course of antibiotics with a single injection, or continuous, longer-term relief from chronic pain and addiction.
Plumb’s first product, an AQL-Naltrexone anti-opioid drug formulation, will provide the longest-acting, injectable medication assisted therapy option on the market. For example, AQL™-Naltrexone requires dosing every 6-8 weeks reducing the opportunity for relapse between doses and fewer clinic visits. This competitive advantage is protected by two issued patents and manufacturing trade secrets owned exclusively by Plumb.